1
00:00:13,060 --> 00:00:16,900
Je travaille sur une maladie musculaire plutôt rare :

2
00:00:16,900 --> 00:00:19,700
la myopathie GNE,

3
00:00:19,700 --> 00:00:22,740
anciennement appelée

4
00:00:22,740 --> 00:00:25,300
myopathie héréditaire à inclusions,

5
00:00:25,300 --> 00:00:29,580
ou myopathie distale à vacuoles bordées.

6
00:00:29,580 --> 00:00:32,340
Il s'agit d'une myopathie se déclarant à l'âge adulte,

7
00:00:32,340 --> 00:00:36,660
commençant dans les muscles distaux des jambes,

8
00:00:36,660 --> 00:00:39,620
et qui s'étend ensuite progressivement

9
00:00:39,620 --> 00:00:43,780
aux membres supérieurs.

10
00:00:43,780 --> 00:00:47,740
Elle se déclare généralement au début de l'âge adulte,

11
00:00:47,740 --> 00:00:49,980
puis la maladie progresse lentement

12
00:00:49,980 --> 00:00:52,660
sur plusieurs décennies,

13
00:00:52,660 --> 00:00:57,140
conduisant à un handicap marqué au fil des ans.

14
00:00:57,140 --> 00:01:02,020
Nous avons récemment lancé un essai clinique de phase 3.

15
00:01:02,020 --> 00:01:06,180
En réalité, il s'agit du premier essai clinique de phase 3

16
00:01:06,180 --> 00:01:08,060
en myopathie distale

17
00:01:08,060 --> 00:01:11,900
ayant été mené, et malheureusement,

18
00:01:11,900 --> 00:01:14,340
il n'a démontré aucune amélioration

19
00:01:14,340 --> 00:01:17,140
avec une supplémentation en acide sialique,

20
00:01:17,140 --> 00:01:19,140
dont la déficience était censée 

21
00:01:19,140 --> 00:01:24,380
être responsable de la maladie

22
00:01:24,380 --> 00:01:29,100
La difficulté de cette étude résidait dans le fait

23
00:01:29,100 --> 00:01:32,860
qu'il s'agissait d'une étude à court-terme comparée

24
00:01:32,860 --> 00:01:35,780
à la progression de la maladie,

25
00:01:35,780 --> 00:01:41,220
et que la gravité des troubles

26
00:01:41,220 --> 00:01:44,780
était très variable selon les personnes:

27
00:01:44,780 --> 00:01:47,780
Certaines d'entre elles ont progressé plus rapidement

28
00:01:47,780 --> 00:01:51,580
as compared to others, and because of that,

29
00:01:51,580 --> 00:01:54,620
la supplémentation n'a pas montré

30
00:01:54,620 --> 00:01:58,340
a positive effect in this trial.

31
00:02:00,300 --> 00:02:03,020
The message is that despite the fact

32
00:02:03,020 --> 00:02:04,740
that this trial has helped,

33
00:02:04,740 --> 00:02:07,740
we have not stopped trying.

34
00:02:07,740 --> 00:02:11,100
First of all, we have learned a few things

35
00:02:11,100 --> 00:02:14,260
from the supplementation with sialic acid,

36
00:02:14,260 --> 00:02:18,220
and a rather similar metabolic approach

37
00:02:18,220 --> 00:02:21,700
is now underway in the United States,

38
00:02:21,700 --> 00:02:25,780
learning from previous problems

39
00:02:25,780 --> 00:02:27,780
that we had in the study,

40
00:02:27,780 --> 00:02:31,020
including outcome measures,

41
00:02:31,020 --> 00:02:35,060
how to follow patients and for how long...

42
00:02:35,060 --> 00:02:41,940
We had in fact a joint meeting, a workshop,

43
00:02:41,940 --> 00:02:45,300
with all leaders in this field,

44
00:02:45,300 --> 00:02:49,370
to try and find a common way of collaboration,

45
00:02:49,370 --> 00:02:51,540
because this is a rare disease,

46
00:02:51,540 --> 00:02:58,880
but it is clustered in some ethnic populations,

47
00:02:58,880 --> 00:03:01,980
which need to be approached.

48
00:03:01,980 --> 00:03:07,700
Some of those are not privileged people,

49
00:03:07,700 --> 00:03:10,500
and because of that, it is hard to conduct

50
00:03:10,500 --> 00:03:15,140
a study in such a population.

51
00:03:15,140 --> 00:03:18,320
However, the disease is a worldwide disease,

52
00:03:18,320 --> 00:03:23,230
and there are probably a couple of dozens

53
00:03:23,230 --> 00:03:26,140
of patients here in France too.

